Table 2.
Pre-therapy participant characteristics.
| Baseline characteristic | Completers (n = 21) | Dropouts (n = 7) |
|---|---|---|
| Sex: (male/female) | 12/9 | 3/4 |
| Age: M (SD) | 33.9 (11.8) | 27.1 (5.9) |
| Age of onset: M (SD) | 27.5 (6.7)‡ | 19.0 (8.9)⁎ |
| Duration of illness: M (SD) | 7.8 (9.9)‡ | 8.0 (6.9) |
| Chlorpromazine equivalents (mg): M (SD) | 520.0 (483.0)a | 354.0 (140.1)b, † |
| PANSS-6: M (SD) | 13.8 (4.2) | 11.3 (4.6) |
| PSP: M (SD) | 49.1 (15.7) | 61.4 (18.8) |
| CANTAB RVPA′: M (SD) | −0.6 (0.8)ζ | −0.2 (0.5)‡ |
| CANTAB SWMBE468: M (SD) | 0.1 (1.6)ζ | −0.4 (1.9)‡ |
| CANTAB OTSPSFC: M (SD) | 0.4 (1.1)ζ | −1.0 (1.3)‡ |
| CVLT-II Trial 5: M (SD) | −0.9 (1.4) | 0.1 (0.4) |
| Diagnoses: (n) | ||
| Schizophrenia | 5 | 2 |
| Schizoaffective disorder | 4 | 2 |
| Delusional disorder | – | 1 |
| Dissociative disorder | 1 | – |
| Mood disorder with psychotic features | 5 | – |
| Other specified SSD | 1 | – |
| Unspecified SSD | 4 | 2 |
| Undiagnosed, high risk for psychosis | 1 | – |
Note. PANSS-6: Positive and Negative Syndrome Scale-6 item. PSP: Personal and Social Performance scale. CANTAB: Cambridge Neuropsychological Test Automated Batteries; RVPA′: Rapid Visual Information Processing task A′, measure of sustained attention; SWMBE468: Spatial Working Memory task: Between errors 468, a measure of spatial working memory; OTSPSFC: One Touch Stockings task: problem solved on first choice, a measure of executive functions including reasoning and problem solving; CVLT-II: California Verbal Learning Test II. All cognitive measures standardized considering age and sex. SSD: schizophrenia-spectrum disorder.
See Supplemental Table S2–S3 for breakdown by therapy group.
indicates p < .05.
One missing result.
Two missing results.
Six missing results.
Four participants not on antipsychotics.
Two participants not on antipsychotics.